Clinical Pharmacokinetics

, Volume 22, Supplement 1, pp 43–47 | Cite as

The Relative Bioavailability of Temafloxacin Administered through a Nasogastric Tube With and Without Enterai Feeding

  • T. J. Lubowski
  • C. H. Nightingale
  • K. Sweeney
  • R. Quintiliani
Section 1: Pharmacokinetics

Summary

The relative bioavailability of a single oral dose of temafloxacin given with and without enterai feeding was determined in 18 healthy male volunteers in a randomised crossover study. Subjects were administered 600mg of temafloxacin orally as an intact tablet, or a crushed tablet suspended in water administered through a nasogastric tube with or without an enterai feeding solution [Osmolite® (Ross) 100 ml/h started 2h before administration of temafloxacin and continued for 4h postdose]. Plasma samples were analysed by a high performance liquid Chromatographic technique. Mean peak plasma concentrations (Cmax) for the oral tablet, crushed tablet, and crushed tablet with enterai feeding solution were 3.95 ± 1.02, 4.85 ± 0.69, and 4.69 ± 0.61 mg/L/70kg, respectively, and mean calculated area under the concentration-time curve from time 0 to 48h (AUC(0–48h)) values were 48.1 ± 11.0,54.5 ± 6.52, and 49.7 ± 5.89 mg/L · h/70kg, respectively. In terms of AUC(0–48h) and Cmax, the relative bioavailability of temafloxacin after nasogastric delivery of crushed temafloxacin given with and without an enterai feeding solution was equivalent to the reference oral regimen.

Keywords

Enteral Feeding Pefloxacin Enoxacin Relative Bioavailability Fleroxacin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bastow MD. Complications of enterai nutrition. Gut 27: S551–S555, 1986CrossRefGoogle Scholar
  2. Gibaldi M, Perrier D. Absorption kinetics and bioavailability. In Pharmacokinetics, 2nd ed., revised and expanded, p. 145, Marcel Dekker Inc., New York, 1982Google Scholar
  3. Granneman RG, Carpenter P, Morrison PJ, Pernet AG. Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrobial Agents and Chemotherapy 35: 436–441, 1991PubMedCrossRefGoogle Scholar
  4. Granneman RG, Varga LA. High performance liquid chromatography for the detection of temafloxacin in biological matrices. Journal of Chromatography, in press, 1991Google Scholar
  5. Grasela TH, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrobial Agents and Chemotherapy 33: 615–617, 1989PubMedCrossRefGoogle Scholar
  6. Hardy DJ, Swanson RN, Hensey DM, Remer NR, Bower RR, et al. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrobial Agents and Chemotherapy 31: 1768–1774, 1987PubMedCrossRefGoogle Scholar
  7. Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Reviews of Infectious Diseases 10 (Suppl 1): 138–139, 1988Google Scholar
  8. Jaehde U, Sörgel F, Koch HU, Stephan U, Gottschalk B, et al. Gastrointestinal and hepatic drug interactions with pefloxacin, a new quinolone. Abstract. Clinical Pharmacology and Therapeutics 42: 166, 1987CrossRefGoogle Scholar
  9. Jones BJM. Enterai feeding: techniques of administration. Gut 27: S47–S50, 1986CrossRefGoogle Scholar
  10. Lode H, Hampel B, Wachter T, Borner K, Koeppe P. Single dose pharmacokinetics of fleroxacin in volunteers, fasting, after standard breakfast and antacids. Abstract. Workshop on Fleroxacin (Ro 23-6240): a new oral once-a-day quinolone. 15th International Congress of Chemotherapy, 19–24 July, 1987Google Scholar
  11. Lode H. Drug interactions with quinolones. Reviews of Infectious Diseases 10 (Suppl. 1): S132–S136, 1988PubMedCrossRefGoogle Scholar
  12. Nix DE, Wilton JH, Schentag JJ, Parpia SH, Norman A, et al. Inhibition of norfloxacin absorption by antacids and sucralfate. Abstract. 2nd International Symposium on New Quinolones, Geneva, 25–27 Aug, 1988Google Scholar
  13. Nye K, Shi YG, Andrews JM, Ashby JP, Wise R. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. Journal of Antimicrobial Chemotherapy 24: 415–424, 1989PubMedCrossRefGoogle Scholar
  14. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 15: 657–680, 1987PubMedGoogle Scholar
  15. Seelmann R, Mahr G, Sorgel F, Gottschalk B, Granneman R, et al. The effect of antacids and cimetidine on the pharmacokinetics of temafloxacin. Program Abstracts, 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, 1989Google Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • T. J. Lubowski
    • 1
  • C. H. Nightingale
    • 1
  • K. Sweeney
    • 1
  • R. Quintiliani
    • 1
  1. 1.Hartford HospitalHartfordUSA

Personalised recommendations